Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $3

Author: Benzinga Newsdesk | November 20, 2023 11:31am
HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $12 to $3.

Posted In: ADCT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist